论文部分内容阅读
目的:分析参麦注射液对阿霉素治疗乳腺癌的疗效以及阿霉素药代动力学的影响,探讨参麦注射液联合阿霉素治疗乳腺癌的临床意义。方法:建立人乳腺癌裸鼠移植瘤模型,将40只模型小鼠随机分为4组,对照组(C组)、阿霉素组(A组)、参麦注射液组(SMI组)、阿霉素+参麦注射液组(A+SMI组),各组给予相应的药物治疗14 d,治疗期每3 d测量肿瘤体积,14 d后处死小鼠,称量瘤体质量,计算抑瘤率;取瘤体,采用免疫组化法检测瘤体中MVD、VEGF;另取瘤体和血浆,采用HPLC法检测瘤体和血浆中阿霉素含量。结果:A组、SMI组、A+SMI组肿瘤生长速度低于C组;A组、SMI组、A+SMI组肿瘤抑制率分别为38.11%、25.98%、54.44%。A组、SMI组、A+SMI组MVD和VEGF表达水平较C组明显下降,A+SMI组MVD和VEGF表达水平相对于A组明显下降,差异均有统计学意义(P<0.05)。A+SMI组肿瘤组织及血浆中阿霉素浓度较A组显著升高,差异有统计学意义(P<0.05)。结论:参麦注射液能提高阿霉素抗乳腺癌的作用,提高其对肿瘤血管的抑制作用,上述作用或许与参麦注射液提高了肿瘤组织中阿霉素的浓度有关。
Objective: To analyze the effect of Shenmai injection on the efficacy of doxorubicin in the treatment of breast cancer and the pharmacokinetics of doxorubicin, and to explore the clinical significance of Shenmai injection combined with doxorubicin in the treatment of breast cancer. Methods: The model of human breast cancer xenografts in nude mice was established. 40 mice were randomly divided into 4 groups: control group (C group), adriamycin group (A group), Shenmai injection group (SMI group) Adriamycin + Shenmai injection group (A + SMI group), each group was given the corresponding drug treatment for 14 days. The tumor volume was measured every 3 days in the treatment group. After 14 days, the mice were sacrificed, the tumor mass was weighed, Tumors were removed. MVD and VEGF were detected by immunohistochemical method. Tumors and plasma were also collected. The contents of doxorubicin in tumor and plasma were determined by HPLC. Results: The tumor growth rate in group A, SMI and A + SMI was lower than that in group C; the tumor inhibition rates in group A, SMI and A + SMI were 38.11%, 25.98% and 54.44%, respectively. The expression of MVD and VEGF in group A, SMI and A + SMI were significantly lower than those in group C, and the levels of MVD and VEGF in group A + SMI were significantly lower than those in group A (P <0.05). The concentration of doxorubicin in tumor tissues and plasma in A + SMI group was significantly higher than that in A group, the difference was statistically significant (P <0.05). Conclusion: Shenmai injection can enhance the effect of doxorubicin on breast cancer and increase its inhibitory effect on tumor blood vessels, which may be related to the increase of the concentration of doxorubicin in tumor tissues by Shenmai injection.